Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in IntraCranial Atherosclerotic diseaSe (CATIS- ICAS)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 1172 participants.

Also called NCT07468448

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 1,172 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07468448
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07468448. Randomized; quadruple masking; primary purpose prevention. Start 2026-09-30 (anticipated); primary completion 2029-12-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in IntraCranial Atherosclerotic diseaSe (CATIS- ICAS)
Acronym
CATIS-ICAS
Condition
Intracranial Atherosclerosis
Intervention (Drug)
Rivaroxaban
Intervention (Drug)
ASA
Lead sponsor
Population Health Research Institute (class: other)

Record details

Record id
cardio:ct-nct07468448
Content hash
0bf11bcac81d93177740e4c53e6b1cbfb44feab5004a8d9241a19a72b10e4d9b